Skip to main content
. 2016 Jan 25;7(8):9448–9461. doi: 10.18632/oncotarget.7021

Figure 3. HBV carrying LFCD mutation inhibited TRAIL-induced cell apoptosis in HepG2 cells.

Figure 3

A. TUNEL assays for HepG2-neo, -pol and -HBV cells after they were treated with 100 ng/mL of TRAIL for 24 h. Cells exhibited green fluorescence were under apoptosis. Nuclei were stained with DAPI. Quantitative comparison for the numbers of apoptotic cells were depicted (right lower panel). B. After treated with TRAIL, HepG2 stable cells were stained with annexin V-FITC and PI for flow cytometric analysis. Lower panel, quantitative comparison of the numbers of apoptotic cells. C. Comparisons of Bcl-xL and cyclin E expression levels after HepG2 cells derived stable transformants (-neo, -pol, and -HBV) were treated with (+) or without (−) TRAIL. GAPDH served as a loading control. Top panel, immunoblot analysis; Middle and bottom panels, quantitative assessments. Values were given in mean ± SD from three independent experiments. “*”, P < 0.05; “**”, P < 0.01.